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The relative risk of immune-mediated disorders (IMDs) among
women carriers of premutation alleles is estimated by a survey
for IMDs among 344 carrier women (age 19–81 years; mean
46.35 and SD12.60) and 72 controls (age 18–87 years;mean 52.40
and SD 15.40). One hundred ﬁfty four (44.77%) women carrier
had at least one IMD, as did 20 controls (27.78%).Amongwomen
carriers, autoimmune thyroid disorder was the most common
(24.4%), then ﬁbromyalgia (10.2%), irritable bowel syndrome
(IBS; 9.9%), Raynaud’s phenomenon (7.6%), rheumatoid arthri-
tis (RA; 3.8%), Sj€ogren syndrome (2.6%), systemic lupus eryth-
ematosus (SLE; 2.03%), multiple sclerosis (1.74%). Of 55
carriers age 40 or older with FXTAS, 72.73% had at least one
IMD, compared to 46.54% of those without FXTAS (n¼ 159),
and 31.58% of controls (n¼ 57). The estimated odds ratio (OR)
for IMD is 2.6 (95% CI 1.2–5.6, P¼ 0.015) for women with
FXTAS relative to those without FXTAS; the likelihood of
IMD in carriers without or with FXTAS was also signiﬁcantly
higher than for controls (OR 2.1, 95% CI 1.1–4.2, P¼ 0.034; OR
5.5, 95%CI 2.4–12.5,P< 0.001, respectively). Similarly, the odds
of having an IMD among carriers with FXPOI is about 2.4 times
higher when compared to carriers without FXPOI (95% CI 1.1
–5.0; P¼ 0.021). The likelihood of IMD in carriers with or
without FXPOI is greater (OR 2.4, 95% CI 1.1–5.0; P¼ 0.021)
compared to that of controls.  2012 Wiley Periodicals, Inc.
Key words: autoimmune; FXTAS; RNA toxicity; ovarian
insufﬁciency
INTRODUCTION
Premutation alleles of the fragile X mental retardation 1 (FMR1)
gene comprise an expanded trinucleotide (CGG) repeat element in
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the 55–200 repeat range, which is located in the 50 untranslated
region of the gene [Maddalena et al., 2001]. The prevalence of the
premutation allele is 1 in 130–259 women and 1 in 250–813men in
the general population [Rousseau et al., 1995; Hagerman, 2008;
Fernandez-Carvajal et al., 2009]. Several disorders are associated
with the premutation allele; including fragile X-associated primary
ovarian insufﬁciency (FXPOI; cessation of menses before age 40)
[Murray et al., 1995; Uzielli et al., 1999; Sullivan et al., 2005];
fragile X-associated tremor/ataxia syndrome (FXTAS) [Hagerman
et al., 2001; Leehey et al., 2007]; psychiatric dysfunction, including
depression and anxiety [Roberts et al., 2009; Bourgeois et al., 2010];
andhypertension [Coffey et al., 2008;Hamlin et al., 2012].Recently,
immune-mediated disorders (IMDs), speciﬁcally autoimmune
thyroid disorder (AITD) and ﬁbromyalgia, were found to be
associated with the premutation in women with FXTAS compared
to age-matched controls [Coffey et al., 2008]. Similar problems in
women premutation carriers were reported by Rodriguez-Revenga
et al. [2009], where 18.6% had FXPOI, 15.9% had thyroid disease,
and 24.4% had chronic muscle pain.
The pathogenesis of premutation disorders is related to a gain-
of-function effect from elevated levels of the expanded CGG-repeat
FMR1mRNA, which is present in all carriers [Tassone et al., 2000;
Greco et al., 2002; Tassone et al., 2007; Shan et al., 2008; Garcia-
Arocena and Hagerman, 2010]. Consistent with this pathogenic
model, FMR1 mRNA is found in the intranuclear inclusions in
carriers with FXTAS [Tassone et al., 2004]; such inclusions are
foundnotonly in theCNS,but also in theperipheral nervous system
and inmany organs including the adrenal, heart, testes and islets of
Langerhans [Hunsaker et al., 2011]. The expanded-CGG-repeat
mRNA is thought to partially sequester proteins (e.g., Sam68
[Sellier et al., 2010b] and Drosha/DGCR8 [Sellier et al., 2010a]
that are important for diverse cellular functions, which leads to a
functional insufﬁciency as is the case for muscleblind-like 1
(MBNL1) in myotonic dystrophy [Wheeler and Thornton, 2007;
Lee and Cooper, 2009; Garcia-Arocena and Hagerman, 2010].
In the current study, we sought to determine the type and
frequency of IMDs present in premutation women who have
participated in our research studies. We also examine the relative
likelihood of IMD in premutation carriers with and without
FXTAS, as well as those with and without FXPOI.
MATERIAL AND METHODS
Participants
Participants comprised 344 premutation women age 19–81 years
(mean 46.35 and SD 12.60) who were recruited through the
Fragile X Treatment and Research Center at the MIND Institute
at University of California, Davis, and who participated in our
genotype–phenotype studyof familieswith fragileX, orour studyof
individuals with FXTAS, between the years 2000 and 2011. The
study also includes 72 women control age 18–87 years (mean 52.40
and SD 15.40). Some of the subjects were included in a previous
article that described results of their medical evaluation (128
premutation carriers and 19 controls) [Coffey et al., 2008]. Fifty-
six of 344 premutation women (16.3%) were diagnosed with
FXTAS utilizing criteria reported by Jacquemont et al. [2003].
METHODS
Wesurveyed the frequencyof IMDs throughmedical history and, in
some cases, the review of medical records, speciﬁcally about the
occurrence of AITD, multiple sclerosis (MS), Sj€ogren syndrome,
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE),
Raynaud’s phenomenon, irritable bowel syndrome (IBS), and optic
neuritis. Table I provides a descriptive reference to these disorders
in reference populations and our control group.
Our medical assessment is described in Coffey et al. [2008], and
includes demographic data, birth history, early developmental
milestones, behavior problems, psychological history, medical
history, neurological history, medications, and medical examina-
tion andneurological examination by physicians (Dr. R.Hagerman
or physicians trained and supervised by her). A subject was con-
sidered to have an IMD if diagnosed and treated by a physician for
that condition. Medical records were requested when an IMD was
identiﬁed. Informed consent was obtained from all subjects who
agreed to participate in our study; the protocol and consent form
TABLE I. Prevalence of Immune-Mediated Disorders Among Women Carriers of FMR1 Premutation Alleles Compared to the General Population
Autoimmune
disorders
Prevalence among 344 women
premutation carrier (%)
Prevalence among
72 women control (%)
Prevalence in reference
populations (%)
AITD 24.42 11.11 2.5 [Bjoro et al., 2000]
Fibromyalgia 10.17 4.17 2.7–4.7 [Branco et al., 2010]
IBS 9.88 6.52 3–20 [Saito et al., 2002]
Raynaud’s phenomenon 7.56 5.56 4.8 [Cakir et al., 2008]
RA 3.78 4.17 0.5 [Carmona et al., 2002]; 1.16
[Symmons et al., 2002]
Sj€ogren syndrome 2.62 N/A 0.5–3 [Gaubitz, 2006]
SLE 2.03 N/A 0.015–0.05 [Gaubitz, 2006]
MS 1.74 N/A 0.002–0.15 [Rosati, 2001]
Optic neuritis 0.58 N/A 0.12 [Rodriguez et al., 1995]
AITD, autoimmune thyroid disorders; IBS, irritable bowel syndrome; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; MS, multiple sclerosis.
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are approved annually by the University of California, Davis,
Institutional Review Board.
Molecular Studies
A blood sample for measurement of CGG repeat size, methylation
status, and FMR1 mRNA levels was obtained from each subject.
FMR1 mRNA quantiﬁcation, Southern blot, and PCR-based gen-
otyping were performed as described previously [Tassone et al.,
2000, 2008].
Statistical Analysis
We included all 416 subjects (344 premutation carriers and 72
controls) in our descriptive analysis to fully summarize IMDs
involved in premutation carriers both with and without FXTAS
(Table II). However, to examine the association between IMDs and
FXTAS, we report results using logistic regressionmodels (adjusted
for age) based on individuals aged 40 or greater. This analysis was
done tomatch the relevant age range for FXTAS, since FXTAS is not
present in teens, and FXPOI by deﬁnition cannot be fully deﬁned
until age 40, resulting in data for 271 subjects. We report odds ratio
(OR) estimates and their associated 95% conﬁdence interval (CI).
The primary outcome in the logistic regression models is deﬁned
as the presence/absence of (any) IMDs. Logistic regression was
also used to assess the association with molecular variables (CGG
repeats, mRNA levels, and activation ratio/AR), as well as the
association of FXPOIwith IMDs. Univariate (unadjusted) analysis,
stratiﬁed by FXTAS/non-FXTAS status, is based on Fisher’s exact
test.
RESULTS
Summary of IMDs in Premutation Carriers and
Controls
Among 344 premutation carrier women, 154 (44.77%) had at least
one IMD. AITD was the most common (24.4% of study
participants), followed by ﬁbromyalgia (10.2%), IBS (9.9%),
Raynaud’s phenomenon (7.6%), RA (3.8%), Sj€ogren syndrome
(2.6%), SLE(2.03%), MS (1.74%), and optic neuritis (0.58%). We
also compared the frequencies of IMDs in premutation carriers
compared to controls. (Tables II– IV). InTable I, the frequencies are
compared with previous estimates in reference populations. Only
ﬁbromyalgia and AITD have been shown to be signiﬁcantly differ-
ent between carriers and controls in a previous study [Coffey et al.,
2008]. Table II summarizes the observed proportions of speciﬁc
IMDs by genotype and FXTAS/non-FXTAS status for carriers, as
well as for controls. We observed signiﬁcant differences between
carrierswith andwithout FXTAS, andbetween carrierswith FXTAS
and controls, only for AITD and ﬁbromyalgia. The observed
prevalences for these IMDs are highest for carriers with FXTAS,
followed by carriers without FXTAS, and then controls; however,
thehigher observedprevalences in carrierswithout FXTASwerenot
statistically different from those of controls. A similar pattern of
resultswasobserved among subjects aged40orolder (Table III).We
note that the results described here (from Table II) should be
interpreted descriptively. Table III, in conjunction with the results
of the next section, provide the basis for inferring the association
between IMDs and FXTAS status.
Association of FXTAS and FXPOI With Immune-
Mediated Disorders
Toassess the possible associationof IMDswith FXTAS, FXPOI, and
FMR1molecular variables, we consider the cohort of women of age
40 or older (cohort summary in Table III; n¼ 271). In this cohort,
40 of 55 (72.73%) of premutation women with FXTAS had IMDs,
compared with 74/159 (46.54%) of carriers without FXTAS, and
18/57 (31.58%) of control. The observed frequencies of IMDs
for carriers of age 40 or older, with and without FXPOI (cohort
summary in Table IV; n¼ 238) are 27/41 (65.85%) for those with
FXPOI, 67/147 (45.58%) for carriers without FXPOI; IMDs were
present in 17/50 (34.00%) of women control. Although the age
ranges are similar forwomen of age 40 or older, themean ages differ
among the three study groups: controls (mean 58.98, SD 8.88)
versus the FXTAS group (mean 63.44, SD 9.80), P¼ 0.006; controls
versus the non-FXTAS carrier group (mean 50.33, SD 7.82)
P< 0.001; and FXTAS versus non-FXTAS groups (P< 0.001).
Thus, we determined the age-adjusted odds ratio for IMDs using
logistic regression. The estimated odds ratio (OR) for IMD is 2.6
(95% CI 1.2–5.6, P¼ 0.015) for women premutation carriers with
FXTAS relative to carriers without FXTAS. Similarly, the likelihood
of IMD in carriers without or with FXTAS was also signiﬁcantly
higher than controls (OR 2.1, 95% CI 1.1–4.2, P¼ 0.034; OR 5.5,
95% CI 2.4–12.5, P< 0.001, respectively). With respect to FXPOI,
the odds ratio of IMDs among women premutation carriers with
FXPOI is about 2.4, higher when compared to carriers without
FXPOI (95% CI 1.1–5.0; P¼ 0.021); similarly, compared to con-
trols without POI, the likelihood of IMD is higher in both carriers
without and with FXPOI (OR 2.0, 95% CI 1.0–4.0, P¼ 0.050; OR
4.8, 95% CI 1.9–11.8, P< 0.001, respectively).
We also examined the association/effects of CGGexpansion size,
FMR1mRNA level, and activation ratio with IMDs, and we found
that none of these measures were associated with IMDs in women
premutation carrier.
DISCUSSION
Premutation alleles of theFMR1 genewere originally thought not to
be associated with clinical symptoms; their signiﬁcance being their
propensity for expansion to a full mutation allele (>200 CGG
repeats) when transmitted by a woman carrier to the next gen-
eration. However, since 2000, it has been recognized that premu-
tation alleles generate 1.5- to 8-fold elevated levels of FMR1mRNA
[Tassone et al., 2000]. The excessive levels of the expanded CGG-
repeat FMR1mRNA result in a gain-of-function ‘‘toxicity,’’ which
is thought to cause psychiatric problems in mid-life, including
depression and anxiety [Roberts et al., 2009; Bourgeois et al., 2010];
FXPOI [Sullivan et al., 2005]; autonomic dysfunction, including
hypertension [Coffey et al., 2008; Hamlin et al., 2012]; and the
progressive neurological disorder, FXTAS, which is usually milder
in women than inmen [Adams et al., 2007; Hagerman et al., 2008].
Prior reports byCoffey et al. [2008] andRodriguez-Revenga et al.
[2009], of IMDs in women premutation carrier provided the
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stimulus for the current study, where a variety of IMDs were
surveyed in the medical history of 344 women carriers and 72
controls, who participated in our studies, either because their
children had fragile X syndrome, or because they themselves
were having some form of clinical involvement (e.g., FXTAS).
Among women (age 40) in the current study, we found that
46.54% of those without FXTAS experienced one or more of the
IMDs surveyed, and the prevalence increased to about 72.73% for
those with FXTAS (compared to 31.58% for the control group).
As FMR1 premutation alleles are common in the general pop-
ulation, our observation of the frequent occurrence of IMDs among
this group implies that there will be a substantial societal impact of
the premutation via the IMD burden, particularly AITD or ﬁbro-
myalgia. Therefore, we suggest that women with the symptoms
described here should be considered for screening using the
fragile X DNA diagnostic test. If the test identiﬁes a premutation
allele, there are treatment implications not only for the patient
[Hagerman et al., 2008], but also for the extended family as other
members of the family tree will typically be positive for the
premutation or full mutation alleles.
Whywomenwith the premutation have an increased propensity
for ﬁbromyalgia and AITD [Coffey et al., 2008] is not known. RNA
toxicity leads (directly or indirectly) to up-regulation of heat shock
proteins (e.g., Hsp70 and aB-crystallin [Wu et al., 2004; Arocena
et al., 2005], which themselves may stimulate immune dysregula-
tion [Georgopoulos and McFarland, 1993]. Hsp70 is involved in
binding antigens and presenting them to the immune system
[Nishikawa et al., 2008]. Autoantibodies to a number of stress
proteins have been identiﬁed in SLE and RA, but their pathogenic
signiﬁcance remains to be established [Winﬁeld and Jarjour, 1991].
In MS, autoantibodies against aB-crystallin (aB-Cry; a small heat
shockprotein) are detectedwhileaB-Cry transcript levels are found
to be up regulated in FXTAS [Arocena et al., 2005].
The expanded CGG-repeat FMR1 mRNA in premutation car-
riers and, in particular, those with FXTAS, is thought to exert its
toxicity principally through sequestration of RNA-binding pro-
teins, including DGCR8, which is critical for processing miRNAs
[Garcia-Arocena and Hagerman, 2010; Sellier et al., 2010a,b].
Indeed a dysregulation of the miRNA processing machinery has
been reported in FXTAS premutation carriers [Sellier et al., 2010b].
Targeted deletions of individual miRNA genes result in mice with
various immune deﬁciencies [Rodriguez et al., 2007; Thai et al.,
2007]. In 2007, the role of miRNA (miRNA precursor family 101/
miR-101) in regulating autoimmunity was discovered in T-cell
lymphocytes in the sanroque mouse. Potential consequences of
miRNA dysregulation in developing IMDs has been investigated
through two pathways, namely, through dysregulation of T cell
function and up-regulation of the innate immune response, the
latter through increased or prolonged inﬂammatory cytokine
production [Lindsay, 2008; Pauley et al., 2009; Dai and Ahmed,
2011; Tomankova et al., 2011]. The sequestration of proteins
important for splicing messages including Sam 68 and the sub-
sequentmis-splicing of a variety ofmessage is also known to lead to
many forms of autoimmune disease including MS, SLE, RA, and
others [Evsyukova et al., 2010]. Finally, a recent report of miRNA
dysregulation was found associated with infertility and corpus
luteum failure in a mouse that is hypomorphic for the Dicer allele
[Otsuka et al., 2008]. Therefore, it is possible that FXPOI may also
be related to miRNA dysregulation secondary to RNA toxicity;
however this hypothesis needs experimental conﬁrmation.
An additional mechanism through which the premutation may
lead to IMDs is stress and emotional dysfunction. The FMR1
premutation leads to dysregulation of the HPA axis, leading in
turn to enhanced release of the stress hormone cortisol, as dem-
onstrated in thepremutationmouse [Brouwer et al., 2008].Cortisol
dysregulation and stress can lead to inﬂammation and activation of
the immune system [Chang et al., 2009]. Levels of anxiety and
depression are increased in premutation carriers [Roberts et al.,
2009; Bourgeois et al., 2011], and magnetic resonance imaging
(MRI) studies have shown that increased levels of anxiety are
associatedwith a decrease in the size of the hippocampus in women
carriers [Adams et al., 2010]. Diffusion tensor imaging (DTI)
studies have also demonstrated early involvement of the insula
and cingulate in premutation carriers well before the onset of
FXTAS [Hashimoto et al., 2011].
The strong association between FXTAS, FXPOI, and IMDs
suggests that the elements of the cellular pathology associated
with FXTAS or FXPOI may stimulate IMDs, or perhaps the
IMD could lead to CNS inﬂammation that could predispose the
individual to develop FXTAS. This latter possibilitymay be the case
in the women carrier, described by Greco et al. [2008], who died of
MS after a 15-year history of disease; on neuropathological study,
therewere demyelinating lesions ofMS in addition to the inclusions
of FXTAS, evidence of the co-occurrence of both disorders. It is also
possible that the loss of neurons or astrocytes in FXTAS further
stimulates an immune response, or that the elevated mRNA levels
themselvesmightdirectly stimulateToll receptors that lead to IMDs
[Dabbagh and Lewis, 2003; Basu and Fenton, 2004]. Future studies
are needed to address these questions.
IMDs have also been described in somemothers of childrenwith
autism [Croen et al., 2005; Keil et al., 2010] and we have recently
become aware of IMD in many mothers of FG syndrome [Opitz
et al., 2008]. The causes of IMDs in these other conditions deserve
further study because some of the mechanisms leading to these
problems may overlap with the mechanisms hypothesized here.
Although a principal strength of the current study is the large
sample size, there are several limitations that should be noted.
Factors/differences in women premutation carriers with and with
out FXTAS (or with and without FXPOI) that could confound
association with IMDs are not currently well understood and,
therefore, not modeled in this work. Our summary of IMDs
in this cohort (e.g., type and frequency of IMD) is descriptive
and may not provide unbiased estimates of prevalence in the
women premutation population. We studied only women with
the premutation because in our experience we have not, with rare
exceptions, observed IMD disease in men with the premutation.
We also have an ascertainment bias toward individuals with
FXTAS because they are recruited in two of our studies, and
women with IMDs may be more likely to be seen in our clinical
and research program. Well-controlled studies and further testing
for biomarkers of immune dysregulation are needed to verify
and/or provide more accurate estimates of IMD prevalence in
this population. However, our ﬁndings here provide a basis for
such studies.
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